July 22, 2022 02:19 PM EDTUpdated 03:51 PM
Pharma

'We will con­tin­ue to fight': Con­tra­cep­tive com­pa­nies re­main hope­ful af­ter House pass­es bill

Nicole DeFeudis

Editor

A day af­ter the House passed a bill that would pro­tect Amer­i­cans’ right to con­tra­cep­tives, biotech ex­ecs say they will keep fight­ing for bet­ter ac­cess …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times